TY - JOUR
T1 - Screening for mutations in the open reading frame and promoter of the β-amyloid precursor protein gene in familial alzheimer's disease
T2 - Identification of a further family with APP717 val→lle
AU - Fidani, Liana
AU - Rooke, Karen
AU - Chartier-harlin, Marie Christine
AU - Hughes, David
AU - Tanzi, Rudi
AU - Mullan, Mike
AU - Roques, Penelope
AU - Rossor, Martin
AU - Hardy, John
AU - Goate, Alison
N1 - Funding Information:
We would like to thank NATO, the MRC, the Mental Health Foundation, Athena Neuroscience, the Alzheimer's Disease Society, the IPSEN Foundation and the Royal Society for financial support and the families for their support and co-operation. We would like to thank Dr. Gerry Higgins and his colleagues for sending us the sequence of exon 6 and 8 primers through the APP Consortium and Drs Bert Bakker, Christine Van Broeckhoven, Raymund Roos, David St. Clair and Merrill Benson for control samples with APP mutations Samples from the FAD families came from the Conell Cell Repository.
PY - 1992/6
Y1 - 1992/6
N2 - Following the identification of mutations in the β-amyloid precursor protein (APP) gene in familial, early onse Alzheimer's disease (AD), we have developed a screening protocol using single strand conformation analysis (SSCA) to screen exon 17 for the known mutations within APP. In addition, we used this protocol to screen the other seventeen exons of APP and a three hundred and thirty base pair regulatory region of the promoter for new mutations in 9 families with early onset AD. Exons 16 and 17, which encode the deposited beta-amyloid peptide, were screened in a further 10 families. Our screening procedure identifies all the reported mutations within APP. While we have identified a further family with APP717 Val→lle, we did not find any previously undescribed mutations. Screening of other exons of APP in 2 families in which we have previously reported mutations at APP717, failed to reveal other sequence abnormalities supporting the hypothesis that the mutations at APP717 cause the disease in these families. These data suggest that mutations in APP are a rare cause of familial early onset AD (3/21 families tested) and that within APP most, possibly all, mutations which cause AD are in exon 17.
AB - Following the identification of mutations in the β-amyloid precursor protein (APP) gene in familial, early onse Alzheimer's disease (AD), we have developed a screening protocol using single strand conformation analysis (SSCA) to screen exon 17 for the known mutations within APP. In addition, we used this protocol to screen the other seventeen exons of APP and a three hundred and thirty base pair regulatory region of the promoter for new mutations in 9 families with early onset AD. Exons 16 and 17, which encode the deposited beta-amyloid peptide, were screened in a further 10 families. Our screening procedure identifies all the reported mutations within APP. While we have identified a further family with APP717 Val→lle, we did not find any previously undescribed mutations. Screening of other exons of APP in 2 families in which we have previously reported mutations at APP717, failed to reveal other sequence abnormalities supporting the hypothesis that the mutations at APP717 cause the disease in these families. These data suggest that mutations in APP are a rare cause of familial early onset AD (3/21 families tested) and that within APP most, possibly all, mutations which cause AD are in exon 17.
UR - http://www.scopus.com/inward/record.url?scp=0026879836&partnerID=8YFLogxK
U2 - 10.1093/hmg/1.3.165
DO - 10.1093/hmg/1.3.165
M3 - Article
C2 - 1303172
AN - SCOPUS:0026879836
SN - 0964-6906
VL - 1
SP - 165
EP - 168
JO - Human Molecular Genetics
JF - Human Molecular Genetics
IS - 3
ER -